Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors

被引：0
|
作者：
Wells A. Messersmith
Antonio Jimeno
David Ettinger
Dan Laheru
Julie Brahmer
Dina Lansey
Yasmin Khan
Ross C. Donehower
Yusri Elsayed
Peter Zannikos
Manuel Hidalgo
机构：
[1] University of Colorado Cancer Center,
[2] Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,undefined
[3] Johnson & Johnson Pharmaceutical Research & Development,undefined
[4] L.L.C.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2008年 / 63卷
关键词：
Dose-finding; Phase I; Gemcitabine; Pharmacokinetics; Trabectedin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：181 / 188
页数：7
相关论文
共 50 条
  • [21] Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
    Ryan, David P.
    Appleman, Leonard J.
    Lynch, Thomas
    Supko, Jeffrey G.
    Fidias, Panagiotis
    Clark, Jeffrey W.
    Fishman, Mayer
    Zhu, Andrew X.
    Enzinger, Peter C.
    Kashala, Oscar
    Cusack, James, Jr.
    Eder, Joseph P.
    CANCER, 2006, 107 (10) : 2482 - 2489
  • [22] Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors
    Duran, I
    Siu, LL
    Chen, EX
    Oza, AM
    Sturgeon, J
    Chin, SF
    Brown, S
    Pond, GR
    Nottage, M
    ANTI-CANCER DRUGS, 2006, 17 (01) : 81 - 87
  • [23] A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors
    Sun, WJ
    Stevenson, JP
    Gallagher, M
    Giantonio, B
    Algazy, K
    Haller, D
    Vaughn, D
    Raskay, BJ
    O'Dwyer, PJ
    CANCER, 2001, 92 (02) : 414 - 419
  • [24] Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors
    Reid, JM
    Qu, WC
    Safgren, SL
    Ames, MM
    Krailo, MD
    Seibel, NL
    Kuttesch, J
    Holcenberg, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) : 2445 - 2451
  • [25] Phase I and pharmacokinetic study of sequential paclitaxel followed by trabectedin (ET-743) in 24-h every 2 weeks in patients with advanced or metastatic cancer
    Chu, Quincy
    Schwartz, Garry
    Patnaik, Amita
    Goldston, Shelly
    Jimeno, J.
    Lopez-Lazaro, Luis
    Izquerido, M.
    Flores, Luis
    Rowinsky, Eric
    ANNALS OF ONCOLOGY, 2004, 15 : 107 - 107
  • [26] WEEKLY GEMCITABINE IN ADVANCED OR METASTATIC SOLID TUMORS - A CLINICAL-PHASE-I STUDY
    POLLERA, CF
    CERIBELLI, A
    CRECCO, M
    CALABRESI, F
    INVESTIGATIONAL NEW DRUGS, 1994, 12 (02) : 111 - 119
  • [27] Experience of the use of trabectedin (ET-743) in patients with advanced soft tissue sarcoma failing doxorubicin and/or ifosfamide in Korea
    Kim, H.
    Ahn, J.
    Lee, H.
    Kim, T. M.
    Lee, J.
    Park, K.
    Sym, S.
    Choi, Y.
    Lee, K.
    Rha, S. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] Irinotecan and gemcitabine in patients with solid tumors: Phase I trial
    Lima, CMSR
    Leong, SS
    Sherman, CA
    Perkel, JA
    Putman, T
    Safa, AR
    Green, MR
    ONCOLOGY-NEW YORK, 2002, 16 (05): : 19 - 24
  • [29] Pharmacokinetics of Ecteinascidin-743 (ET-743) in three phase I studies
    Hillebrand, MJX
    Jimeno, J
    Cvitkovic, E
    Hoekman, K
    Hoppener, F
    Twelves, C
    Villalona, M
    Rosing, H
    Beijnen, JH
    ANNALS OF ONCOLOGY, 1998, 9 : 119 - 119
  • [30] Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis®) in cancer patients
    Jose Perez-Ruixo, Juan
    Zannikos, Peter
    Hirankarn, Sarapee
    Stuyckens, Kim
    Ludwig, Elizabeth A.
    Soto-Matos, Arturo
    Lopez-Lazaro, Luis
    Owen, Joel S.
    CLINICAL PHARMACOKINETICS, 2007, 46 (10) : 867 - 884
12345